Cargando…
Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin
BACKGROUND: Dysregulation of microRNAs has been reported to be responsible for drug resistance of cancers. However, the association between aberrant expression of miR-26b and cisplatin resistance in non-small cell lung cancer (NSCLC) remains unclear. METHODS: PC9 and A549 were used to establish the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751336/ https://www.ncbi.nlm.nih.gov/pubmed/31686855 http://dx.doi.org/10.2147/OTT.S212649 |
_version_ | 1783452603078672384 |
---|---|
author | Zang, Shuzhi Zhao, Shasha Gao, Xinyuan Li, Yunxia Zhong, Chunlei Gao, Jianlian |
author_facet | Zang, Shuzhi Zhao, Shasha Gao, Xinyuan Li, Yunxia Zhong, Chunlei Gao, Jianlian |
author_sort | Zang, Shuzhi |
collection | PubMed |
description | BACKGROUND: Dysregulation of microRNAs has been reported to be responsible for drug resistance of cancers. However, the association between aberrant expression of miR-26b and cisplatin resistance in non-small cell lung cancer (NSCLC) remains unclear. METHODS: PC9 and A549 were used to establish the cisplatin resistance models on NSCLC. Expression of miR-26b in cisplatin-resistant PC9 and A549 cells (PC9/R and A549/R) was detected by quantitative real-time PCR assays. Drug sensitivity and mitochondrial apoptosis were detected by Cell Counting Kit-8 assay and flow cytometry assay, respectively. The target relationship between miR-26b and tafazzin (TAZ) was validated by dual-luciferase reporter assay. RESULTS: Obvious downregulation of miR-26b was observed in PC9/R and A549/R cells. Restoration of miR-26b partially reversed the cisplatin resistance of PC9/R and A549/R cells. Expression of TAZ was increased in PC9/R and A549/R cells compared to the parental PC9 and A549 cells. Results of dual-luciferase reporter assays verified that TAZ was targeted by miR-26b. We showed that restoration of miR-26b expression inhibited the TAZ expression and thus expanded the mitochondrial pathway of apoptosis induced by cisplatin in PC9/R and A549/R cells. CONCLUSION: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting TAZ. miR-26b/TAZ axis may represent a potential strategy to reverse the cisplatin in NSCLC. |
format | Online Article Text |
id | pubmed-6751336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67513362019-11-04 Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin Zang, Shuzhi Zhao, Shasha Gao, Xinyuan Li, Yunxia Zhong, Chunlei Gao, Jianlian Onco Targets Ther Original Research BACKGROUND: Dysregulation of microRNAs has been reported to be responsible for drug resistance of cancers. However, the association between aberrant expression of miR-26b and cisplatin resistance in non-small cell lung cancer (NSCLC) remains unclear. METHODS: PC9 and A549 were used to establish the cisplatin resistance models on NSCLC. Expression of miR-26b in cisplatin-resistant PC9 and A549 cells (PC9/R and A549/R) was detected by quantitative real-time PCR assays. Drug sensitivity and mitochondrial apoptosis were detected by Cell Counting Kit-8 assay and flow cytometry assay, respectively. The target relationship between miR-26b and tafazzin (TAZ) was validated by dual-luciferase reporter assay. RESULTS: Obvious downregulation of miR-26b was observed in PC9/R and A549/R cells. Restoration of miR-26b partially reversed the cisplatin resistance of PC9/R and A549/R cells. Expression of TAZ was increased in PC9/R and A549/R cells compared to the parental PC9 and A549 cells. Results of dual-luciferase reporter assays verified that TAZ was targeted by miR-26b. We showed that restoration of miR-26b expression inhibited the TAZ expression and thus expanded the mitochondrial pathway of apoptosis induced by cisplatin in PC9/R and A549/R cells. CONCLUSION: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting TAZ. miR-26b/TAZ axis may represent a potential strategy to reverse the cisplatin in NSCLC. Dove 2019-09-13 /pmc/articles/PMC6751336/ /pubmed/31686855 http://dx.doi.org/10.2147/OTT.S212649 Text en © 2019 Zang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Zang, Shuzhi Zhao, Shasha Gao, Xinyuan Li, Yunxia Zhong, Chunlei Gao, Jianlian Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin |
title | Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin |
title_full | Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin |
title_fullStr | Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin |
title_full_unstemmed | Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin |
title_short | Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin |
title_sort | restoration of mir-26b expression partially reverses the cisplatin resistance of nsclc by targeting tafazzin |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751336/ https://www.ncbi.nlm.nih.gov/pubmed/31686855 http://dx.doi.org/10.2147/OTT.S212649 |
work_keys_str_mv | AT zangshuzhi restorationofmir26bexpressionpartiallyreversesthecisplatinresistanceofnsclcbytargetingtafazzin AT zhaoshasha restorationofmir26bexpressionpartiallyreversesthecisplatinresistanceofnsclcbytargetingtafazzin AT gaoxinyuan restorationofmir26bexpressionpartiallyreversesthecisplatinresistanceofnsclcbytargetingtafazzin AT liyunxia restorationofmir26bexpressionpartiallyreversesthecisplatinresistanceofnsclcbytargetingtafazzin AT zhongchunlei restorationofmir26bexpressionpartiallyreversesthecisplatinresistanceofnsclcbytargetingtafazzin AT gaojianlian restorationofmir26bexpressionpartiallyreversesthecisplatinresistanceofnsclcbytargetingtafazzin |